Experienced in Pernicious Anemia

Dr. Karen G. Zeman

Hematology Oncology
National Naval Medical Ctr, 8901 Rockville Pike, 
Bethesda, MD 
Experienced in Pernicious Anemia
National Naval Medical Ctr, 8901 Rockville Pike, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karen Zeman is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Zeman is rated as an Experienced provider by MediFind in the treatment of Pernicious Anemia. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Pernicious Anemia, Lung Cancer, and Lymphofollicular Hyperplasia.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Pernicious Anemia.

Specialties
Hematology Oncology
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

National Naval Medical Ctr, 8901 Rockville Pike, Bethesda, MD 20889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Expanded Access Intermediate-Size Patient Population Protocol
Expanded Access Intermediate-Size Patient Population Protocol
Enrollment Status: Available
Publish Date: October 20, 2022
Intervention Type: Drug
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Unknown
Publish Date: October 15, 2021
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

9 Total Publications

Approach to Pancytopenia in a Deployed Service Member.
Approach to Pancytopenia in a Deployed Service Member.
Journal: Federal practitioner : for the health care professionals of the VA, DoD, and PHS
Published: November 25, 2022
Similar Doctors
Distinguished in Pernicious Anemia
Dr. Stuart E. Selonick
Hematology Oncology | Hematology | Oncology
Distinguished in Pernicious Anemia
Dr. Stuart E. Selonick
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

10710 Charter Dr, Suite G020, 
Columbia, MD 
 (18.4 miles away)
410-964-2218
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stuart Selonick is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Selonick is rated as a Distinguished provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Idiopathic Neutropenia, and Lung Cancer. Dr. Selonick is currently accepting new patients.

Advanced in Pernicious Anemia
Dr. Henry B. Fox
Hematology Oncology | Hematology | Oncology
Advanced in Pernicious Anemia
Dr. Henry B. Fox
Hematology Oncology | Hematology | Oncology

Privia Medical Group, LLC

5530 Wisconsin Ave, Suite 650, 
Chevy Chase, MD 
 (2.6 miles away)
202-296-2440
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Fox is a Hematologist Oncology specialist and a Hematologist in Chevy Chase, Maryland. Dr. Fox is rated as an Advanced provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Antiphospholipid Syndrome, Glossitis, and Pernicious Anemia. Dr. Fox is currently accepting new patients.

Advanced in Pernicious Anemia
Dr. Vinni Juneja
Hematology Oncology | Hematology | Oncology
Advanced in Pernicious Anemia
Dr. Vinni Juneja
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

10710 Charter Dr, Suite G020, 
Columbia, MD 
 (18.4 miles away)
410-964-2218
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Vinni Juneja is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Juneja is rated as a Distinguished provider by MediFind in the treatment of Pernicious Anemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Thrombocytopenia, and Paget Disease of the Breast. Dr. Juneja is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zeman's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile